Le Lézard
Classified in: Business
Subject: ATY

INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Cancer Genetics, Inc. - CGIX


NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Cancer Genetics, Inc. ("Cancer Genetics" or the "Company") (Nasdaq: CGIX) relating to its merger with StemoniX. Under the terms of the agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock, with current shareholders of Cancer Genetics expected to own 22% of the common stock of the combined company.

Monteverde_Associates_PC_Logo

The investigation focuses on whether Cancer Genetics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process and 2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information: https://www.monteverdelaw.com/case/cancer-genetics-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.  Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own stock in Cancer Genetics, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Cell: (646) 522-4840

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC


These press releases may also interest you

at 16:36
Dunkin' Brands Group, Inc., , the parent company of two of the world's most recognized brands, Dunkin' and Baskin-Robbins, confirms that it has held preliminary discussions to be acquired by Inspire Brands. There is no certainty that any agreement...

at 15:49
Current Cloud Backlog of ?6.6 Billion, Up 16% At Constant Currencies IFRS Cloud Gross Margin Up 1.8pp; Non-IFRS Cloud Gross Margin Up 0.7pp At Constant Currencies IFRS Operating Margin Down 2.2pp; Non-IFRS Operating Margin Up 1.3pp At Constant...

at 14:05
Celanese Corporation , a global chemical and specialty materials company, today reported third quarter GAAP diluted earnings per share of $1.76 and adjusted earnings per share of $1.95. The Company recorded net sales of $1.4 billion driven by 20...

at 13:00
Blue Butterfly, a strategic consultancy for the retail real estate industry, announces the appointment of Christie Sparks as Director, Business Development. Sparks will support business development on behalf of clients as well as client acquisition...

at 12:10
Totaling a recently-purchased car is an extremely unpleasant situation. The insurance company will pay only the Actual Cash Value. Cars lose a significant portion of their value as soon as they leave the lot. The owner may be reimbursed with less...

at 10:45
Mirati Therapeutics, Inc. , a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRAS selective inhibitor programs. The preliminary results included updated clinical data of adagrasib (MRTX849),...



News published on 31 august 2020 at 11:36 and distributed by: